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###### Clinical and pathological patient characteristics.
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                                                                     All patients     Matched patients                                                   
  ------------------------------------------------------------------ ---------------- ------------------ ------------- ---------------- ---------------- -------------
  n                                                                  47               68                               34               34               
  Ileal conduit / cutaneous ureterostomy, n =                        17 / 30                                           14 / 20                           
  Median age[\*](#t001fn001){ref-type="table-fn"}, years (IQR)       67 (64--76)      68 (58--71)        *0*.*018*     66 (61--72)      68 (58--71)      *0*.*437*
  Gender[\*](#t001fn001){ref-type="table-fn"} (M/F), n =             39 / 8           47 / 21            *0*.*126*     26 / 8           27 / 7           *0*.*770*
  Mean ECOG-PS[\*](#t001fn001){ref-type="table-fn"} (±SD)            0.0±0.2          0.0±0.0            *0*.*160*     0.1±0.2          0.0±0.0          *0*.*156*
  Median follow-up, months (IQR)                                     72 (53--112)     97 (70--125)       *0*.*093*     73 (54--98)      101 (74--126)    *0*.*139*
  Neoadjuvant chemotherapy, n =                                      18 (38%)         35 (51%)           *0*.*186*     13 (38%)         16 (47%)         *0*.*624*
  TNM classification                                                                                                                                     
      cT[\*](#t001fn001){ref-type="table-fn"} (±SD)                  2.4±0.9          2.3±0.8            *0*.*259*     2.4±0.9          2.2±0.8          *0*.*212*
      pT (±SD)                                                       2.1±1.2          1.4±1.2            *0*.*001*     2.0±1.2          1.3±1.1          *0*.*009*
      pN+, n =                                                       7 (15%)          1 (1.5%)           *0*.*008*     6 (18%)          1 (3%)           *0*.*105*
  Cardiovascular disease[\*](#t001fn001){ref-type="table-fn"}, n =   3 (6%)           9 (13%)            *0*.*354*     2 (6%)           1 (3%)           *0*.*555*
  Hypertension[\*](#t001fn001){ref-type="table-fn"}, n =             21 (45%)         27 (40%)           *0*.*701*     14 (41%)         14 (41%)         *1*.*000*
  Diabetes[\*](#t001fn001){ref-type="table-fn"}, n =                 5 (11%)          8 (12%)            *1*.*000*     5 (15%)          6 (18%)          *0*.*742*
  Median blood loss, kg (IQR)                                        1.5 (0.9--2.3)   1.3 (0.9--2.0)     *0*.*131*     1.4 (1.1--1.9)   1.3 (0.9--1.6)   *0*.*153*
  Median operative duration, hours (IQR)                             4.7 (4.0--6.3)   5.0 (4.4--6.2)     *0*.*897*     4.8 (4.0--6.2)   4.8 (4.5--6.0)   *0*.*789*
  Postoperative Complications, n =                                   18 (38%)         26 (38%)           *1*.*000*     19 (56%)         19 (56%)         *1*.*000*
  Postoperative hydronephrosis (\> G1), n =                          16 (34%)         5 (7%)             *\<0*.*001*   12 (35%)         4 (12%)          *0*.*043*
  Ureteral stent, n =                                                23 (49%)         0 (0%)             *\<0*.*001*   15 (44%)         0 (0%)           *\<0*.*001*
      Ileal conduit, stent (+)                                       2 (12%)                                           1 (7%)                            
      Cutaneous ureterostomy, stent (+)                              21 (70%)                                          14 (70%)                          
  Recurrence, n =                                                    15 (32%)         6 (9%)             *0*.*003*     10 (29%)         2 (6%)           *0*.*023*
  Chemotherapy for recurrent disease, n =                            14 (30%)         4 (6%)             *0*.*001*     9 (27%)          1 (2.9%)         *\<0*.*001*
  Median cycle (IQR)                                                 4 (2--6)         4 (1--5)           *0*.*413*     6 (3--14)        3 (1--4)         *0*.*029*

\* applied for propensity score-matching SD, standard deviation; IQC, interquartile range.
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###### Multivariate Cox regression analyses of risk factors for postoperative stage 3B CKD (eGFR \< 45 mL/min/1.73 m^2^).

Incontinent urinary diversion was divided into 2 groups, and compared with orthotopic ileal neobladder in the model 2. Comorbidities included past history of CVD, HTN, or DM.
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  Variables (Model 1)                   Fisk factors             *P value*   HR     95%CI
  ------------------------------------- ------------------------ ----------- ------ ------------
  Age                                   Older than 67 years      *0*.*043*   2.90   1.03--8.13
  Comorbidities                         Pre-existing             *0*.*110*   2.40   0.82--7.02
  eGFR before surgery                   \< 60 ml/min/1.73m2      *0*.*020*   3.25   1.20--8.80
  Stent indwelling                      Positive                 *0*.*163*   0.40   0.11--1.45
  Postoperative hydronephrosis          Greater than grade 1     *0*.*002*   5.15   1.81--14.6
  Tumor recurrence                      Positive                 *0*.*900*   0.91   0.22--3.71
  Chemotherapy for recurrent disease    Positive                 *0*.*290*   0.43   0.09--2.04
  Urinary diversion                     Incontinent diversion    *0*.*016*   4.41   1.33--14.7
  **Variables (Model 2)**                                                           
  Age                                   Older than 67 years      *0*.*025*   3.47   1.17--10.4
  Comorbidities                         Pre-existing             *0*.*129*   2.32   0.78--6.87
  eGFR before surgery                   \< 60 ml/min/1.73m2      *0*.*016*   3.32   1.25--8.82
  Stent indwelling                      Positive                 *0*.*065*   0.22   0.04--1.10
  Postoperative hydronephrosis          Greater than grade 1     *0*.*003*   4.81   1.70--13.7
  Tumor recurrence                      Positive                 *0*.*969*   0.97   0.23--4.11
  Chemotherapy for recurrent disease    Positive                 *0*.*196*   0.33   0.06--1.77
  Urinary diversion (ref. neobladder)   Cutaneous ureterostomy   *0*.*012*   8.92   1.63--48.7
                                        Ileal conduit            *0*.*069*   3.44   0.91--13.1
